FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in Diabetic Cardiomyopathy Authors: Xin-xin Chen, Yan Gu, Zhe Yin, Yu-tang Li, Zhan-chuan Ma, Wei Wang, Yun-qing Hou, Xiang Wang Published: 2025 ABSTRACT AbstractConsidering the global prevalence of diabetes, diabetic cardiomyopathy (DCM), as a significant diabetes complication, remains a major human challenge; while previous studies have identified ferroptosis as an important underlying mechanism, the unclear regulatory mechanisms hamper the development of therapy for DCM. In this study, we reveal that the expression of the fat mass and obesity-associated protein (FTO) is downregulated in DCM. Overexpression of FTO was found to enhance cardiac function by inhibiting ferroptosis. Mechanistically, acyl - CoA synthetase long - chain family 4 (ACSL4), a key positive mediator of ferroptosis, was identified as a direct target of FTO. The ameliorative effect of FTO was contingent upon the inhibition of ACSL4, and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Furthermore, we demonstrate that nicotinamide mononucleotide and sulforaphane can synergistically suppress ferroptosis by targeting distinct pathways, thereby better alleviating cardiac dysfunction. Collectively, our findings uncover an FTO - ACSL4 regulatory axis that plays a crucial role in the pathogenesis of DCM, offering valuable insights for the development of therapeutic strategies against DCM.Graphical abstract Schematic representation of FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in diabetic cardiomyopathy (DCM). FTO is downregulated in DCM, which leads to increased methylation of Acsl4 transcripts. This epigenetic modification results in elevated levels of Acsl4 mRNA and ACSL4 protein, which subsequently induces lipid peroxidation and ferroptosis. The attenuation of FTO-mediated ferroptosis is thus achieved through an ACSL4-dependent manner. Importantly, based on our previous study, NMN targeting FTO combined with SFN targeting NRF2 could synergistically inhibit ferroptosis, reducing lipid peroxidation and ferroptosis, and ultimately ameliorating DCM. DM, diabetes mellitus; FTO, fat mass and obesity-associated protein; DCM, diabetic cardiomyopathy; ACSL4, acyl-CoA synthetase long-chain family member 4; SLC7A11, solute carrier family 7 member 11; NMN, mononucleotide; SFN, sulforaphaneSupplementary InformationThe online version contains supplementary material available at 10.1007/s12012-025-10080-w.Keywords: Ferroptosis, Diabetic cardiomyopathy, Lipid peroxidation, Fat mass and obesity associated protein, Acyl-CoA synthetase long-chain family 4 Introduction The global prevalence of diabetes among 20–79-year-old individuals was estimated at 10.5% (536.6 million people) in 2021 and is projected to rise to 12.2% (783.2 million) in 2045, with corresponding global diabetes-related health expenditures at 966 billion USD and 1,054 billion USD, respectively [1]. Diabetic cardiomyopathy (DCM), which was first described nearly 50 years ago [2], is the major cause of heart failure in patients with diabetes [3]. Despite extensive preclinical and clinical studies on DCM in recent decades, its pathogenesis has not yet been fully elucidated, limiting therapeutic options. Ferroptosis is a nonapoptotic form of regulated cell death induced by the iron-dependent overproduction of phospholipid hydroperoxides [4, 5]. Iron overload in individuals with diabetes not only increases the risk of insulin resistance and diabetes progression but also aggravates cardiovascular complications [6–8]. Previous studies, including our own, have provided evidence that ferroptosis plays an essential role in DCM pathogenesis in mice [9, 10] and humans [11]. Furthermore, sulforaphane (SFN), which prevents ferroptosis, partly improves heart function via AMPK-mediated NRF2 activation and downstream SLC7A11 and Ferritin H expression [9]. However, the regulatory mechanisms involved in ferroptosis have not yet been fully elucidated due to its complex nature. Fat mass and obesity-associated protein (FTO), an m6A demethylase central to the dynamic epitranscriptomic regulation of RNAs, greatly influences various aspects of the RNA lifecycle, including splicing, export, decay, and translation [12]. FTO is downregulated during diabetes [13, 14], and targeting FTO could improve heart function in DCM [13]. However, the underlying mechanisms remain unclear. Furthermore, FTO ameliorates doxorubicin-induced cardiotoxicity [15] and septic cardiomyopathy [16] by inhibiting ferroptosis. However, the potential of FTO to ameliorate DCM through ferroptosis inhibition and its underlying molecular mechanism remains largely unexplored. In this study, we aimed to determine the role of FTO in inhibiting ferroptosis during DCM and the underlying mechanisms, utilizing advanced glycation end-product (AGE)-exposed engineered cardiac tissues (ECTs) (a unique ex vivo DCM model) and type 2 diabetes (T2D) mouse models. Our findings provide insights that could aid in the development of novel DCM treatments targeting ferroptosis. Materials and methods Animals C57BL/6J, Acsl4flox/flox (Acsl4fl/fl), Myh6-CreERT2 mice were purchased from Cyagen Biosciences Inc. (Guangzhou, China). To generate Myh6-CreERT2/Acsl4fl/fl (Acsl4-CKO) mice, we crossed Acsl4fl/fl mice with Myh6-CreERT2 mice. These mice were carefully selected to ensure similar age and weight. Acsl4fl/fl littermates were used as controls. Only male mice were included in the study due to the high resistance of females to a high-fat diet (HFD) + streptozotocin (STZ)-induced cardiomyopathy [17]. All mice were housed at the Translational Medicine Research Institute of Jilin University First Hospital (Jilin University, Jilin, China). All animal procedures were approved by the Institutional Animal Care and Use Committee of the hospital (2022 − 0401) and were performed according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health. Mice were kept at 22 °C, with a 12-h light/dark cycle, and were provided free access to standard rodent chow and tap water. T2D mice with DCM were established and characterized elsewhere [18]. Briefly, 8-week-old WT and Acls4-CKO mice were fed an HFD for 3 months to induce insulin resistance, followed by a single intraperitoneal injection of STZ (in 0.1 mol/L of citrate acid buffer, 60 mg/kg) to induce partial insulin deficiency [18, 19] and hyperglycemia (fasting blood glucose ≥ 220 mg/dl), 7 days after STZ injection. Age-matching mice were fed a normal diet (ND) for 3 months, and used as a control. Next, T2D and control mice were injected 5 days a week subcutaneously, with FB23-2 (Selleck, Houston, TX, USA; 2 mg/kg) [20], or SFN (Sigma–Aldrich, Huntington, MA, USA; 0.5 mg/kg), Nicotinamide Mononucleotide (NMN, Selleck, Houston, TX, USA) was dissolved in water at 100mM [21], except for the control mice, for 3 months and exposed to continual HFD or ND. When SFN, or NMN treatment was completed, mice were fed an HFD or ND for an additional 3 months until being euthanized 6 months after T2D onset. For mice with time gradient, mice were euthanized 0, 3, 6 months after T2D onset. Each group contained four to six mice. Isolation of Neonatal Mouse Ventricular Cardiac Cells and ECT Construction As recently described [22], Heart cells were isolated from C57BL/6J pups within 3 days of birth, and ECTs were constructed as previously described [22, 23]. ECTs were maintained in culture medium for 3–15 days, and the medium was changed every 3 days [22]. On day 4, they were treated with AGEs (150 µg/ml, Sigma-Aldrich, Huntington, MA, USA) or bovine serum albumin (BSA 150 µg/ml, as a control for AGEs; Sigma-Aldrich). The AGE-containing medium was changed every 3 days and maintained for 15 days to induce dysfunction. Echocardiography Cardiac function was evaluated using transthoracic echocardiography. Mice were anesthetized with avertin, placed supine on a temperature-controlled platform, and analyzed using a high-resolution system (Vevo 2100; FUJIFILM Visual Sonics, Toronto, Canada) equipped with a high-frequency ultrasound probe. The indices of cardiac systolic function (ejection fraction and fractional shortening) and diastolic function (E/A, E/e’, and deceleration time) were calculated using the Vevo 2100 software. The data were averaged over 10 cardiac cycles. Isolation of RNA and Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) Ptgs2,Coll-1α1, Coll-IIIα1, Ctgf, Fn1, Myh7and β-actin expression were determined using RT-qPCR, as described previously [22, 23]. All primers were purchased from Thermo Fisher Scientific. RT-qPCR was performed in a 20-µl volume (10 µl of TaqMan Universal PCR Master Mix, 1 µl of primer, and 9 µl of cDNA) using the ABI 7300 Real-Time PCR system. Fold differences in expression between different samples were determined based on the comparative cycle time (CT), and the CT value was normalized to that of the endogenous reference gene (β-actin). Histopathological Analysis Heart tissue was embedded in paraffin and sectioned, as previously described [24]. The tissues were fixed in 10% buffered formalin, followed by paraffin embedding and sectioning at a thickness of 5 μm. To assess collagen deposition in cardiac tissues, we used Picro-Sirius Red staining. All stained sections were examined under an Olympus BX43 microscope (Olympus Life Science, Tokyo, Japan), and images were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Determination of Lipid Peroxidation Cardiac lipid peroxidation levels were examined by measuring malondialdehyde (MDA) formation (ab233471, Abcam, Cambridge, UK), following the manufacturer’s instructions. Determination of Brain Natriuretic Peptide Plasma was prepared from blood via centrifugation at 8000 g for 10 min at 4 °C. According to the manufacturer’s protocol, plasma brain natriuretic peptide (BNP) level was measured using a mouse BNP-specific ELISA kit (EIAM-BNP-1; RayBiotech, Peachtree Corners, GA, USA). Protein Extraction and Western Blotting Protein extraction from ECTs or cardiac tissues and subsequent western blotting were performed as previously described [22, 23]. Antibodies against acyl-CoA synthetase long-chain family member 4 (ACSL4; 1:1000), ferritin heavy chain (FTH1, 1:1000), ATF3 (1:1000), and FTO (1:1000) were purchased from Cell Signaling Technology (Danvers, MA, USA). The antibody against β-actin (1:3000) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA), and the anti-rabbit/anti-mouse horseradish peroxidase-linked secondary antibody (1:5000) was purchased from Cell Signaling Technology. Statistical Analyses Data were analyzed using GraphPad Prism 9 (San Diego, CA, USA). Data are presented as the normalized mean ± standard deviation. Statistical differences were determined using a two-sided unpaired Student’s t-test or two-way analysis of variance, followed by Tukey’s multiple comparison test. A p-value of < 0.05 was considered significant (*p < 0.05, **p < 0.01, ***p < 0.001, and ns p > 0.05). Biological replicates yielded comparable results, and no technical or biological replicates were excluded. Sample sizes for all experiments were predetermined based on our experience and published literature. Investigators were blinded to group allocation during the experiments and outcome assessments. Results FTO Is Negatively Correlated with Ferroptosis during DCM Progression To define the role and mechanism of FTO in DCM, we first test the expression of FTO in both AGEs induced engineered cardiac tissue (in vitro DCM model) and cardiac tissues of diabetic mice. The mRNA and protein levels of FTO were downregulated in both models (Fig. 1a and d). To further define the role of FTO during the progression of DCM, we established a mouse model of DCM with time gradient (0, 3, 6 months after diabetes), and found that with the extension of onset diabetes, the level of FTO continued to decrease (Fig. 1e), accompanied with the rise of the level of MDA (lipid peroxidation, a hallmark of ferroptosis, Fig. 1f) and the level of Ptgs2 mRNA (ferroptosis marker gene, Fig. 1g). Correspondingly, indicators of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf and Fn1, Fig. 1h) and myocardial hypertrophy (Nppa and Myh7, Fig. 1i), which represent cardiac remodeling, progressively worsened. This was accompanied by a sustained decline in cardiac diastolic function (assessed by cardio-ultrasonography shown in Fig. 1j and m and plasma BNP, a biomarker of heart dysfunction, shown in Fig. 1n). Therefore, FTO was downregulated in diabetic cardiac tissues and negatively correlated with cardiomyocytes ferroptosis during DCM progression. FTO is negatively correlated with ferroptosis during the progression of DCM. a Fto expression in AGE-treated ECTs, assessed using RT-qPCR; n = 6 per group. b Fto expression in diabetic cardiac tissues, assessed using RT-qPCR; n = 5 per group. c AGE-induced FTO expression in ECTs, assessed using western blotting; n = 6 per group. d FTO expression in diabetic cardiac tissues, assessed using western blotting; n = 5 per group. e FTO expression in control and diabetic cardiac tissues (0, 3, and 6 months after diabetes), assessed using western blotting; n = 4 per group. f Lipid peroxidation in diabetic cardiac tissues (0, 3, and 6 months after diabetes), confirmed by observing the changes in MDA levels; n = 4 per group. g Expression of Ptgs2 in diabetic cardiac tissues (0, 3, and 6 months after diabetes induction), assessed using RT-qPCR. n = 4 per group. h Markers of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf, and Fn1) in diabetic cardiac tissues (0, 3, and 6 months after diabetes induction), assessed using RT-qPCR. n = 4 per group. i Markers of cardiac hypertrophy (Nppa and Myh7) in diabetic cardiac tissues (0, 3, and 6 months after diabetes induction), assessed using RT-qPCR. n = 4 per group. j–m Diastolic function (0, 3, and 6 months after diabetes induction), assessed using cardio-ultrasonography. n = 4 per group. n Heart function (0, 3, and 6 months after diabetes induction), assessed based on the plasma levels of BNP. n = 4 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. T2D type 2 diabetes model, BSA bovine serum albumin, DM diabetes mellitus, FTO fat mass and obesity-associated protein, AGE advanced glycation end-product, ECT engineered cardiac tissue, RT-qPCR quantitative real-time polymerase chain reaction, MDA malondialdehyde, BNP brain natriuretic peptide FTO Could Improve Heart Function in DCM Through the Regulation of Ferroptosis To define the role of FTO in DCM mediated by ferroptosis, we established mice models of DCM and treated them with FB23-2, a small molecule that specially inhibits the demethylase activity of FTO. In accordance with previous studies [25] and the pharmacological mechanism [20] of FB23-2, it didn’t affect the expression of FTO (Fig. 2a) and had no effect on plasma glucose and body weight (Fig. S3a-b, 3i), but could aggravate the heart function in DCM (Fig. 2b-e). Moreover, the levels of MDA and Ptgs2 mRNA which are indicators of ferroptosis furtherly elevated after FB23-2 treatment (Fig. 2f and g). Correspondingly, indicators of cardiac fibrosis (collagen accumulation accessed through Picro-Sirius Red staining shown in Fig. 2h-i; Coll-1α1, Coll-IIIα1, Ctgf and Fn1 accessed by RT-PCR shown in Fig. 2j) and myocardial hypertrophy (Nppa and Myh7 tested via RT-PCR shown in Fig. 2k, heart weight/tibial length shown in Fig. 2l), which represent cardiac remodeling, progressively worsened after FB23-2 treatment. Inhibition the demethylase activity of FTO aggravate ferroptosis in DCM. a FTO expression in cardiac tissues of different groups, assessed using western blotting; n = 4–5 per group. b–d Diastolic function in cardiac tissues of different groups, assessed using cardio-ultrasonography. n = 4–5 per group. e Heart function in cardiac tissues of different groups, assessed by plasma levels of BNP. n = 4–5 per group. f Lipid peroxidation in diabetic cardiac tissues of different groups, confirmed by observing the changes in MDA levels; n = 4–5 per group. g Expression of Ptgs2 in diabetic cardiac tissues of different groups, assessed using RT-qPCR. n = 4–5 per group. h Picro-Sirius Red staining results of heart tissue sections. i Quantitative analysis of Picro-Sirius Red staining for collagen accumulation. n = 4–5 per group. j Markers of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf and Fn1) in diabetic cardiac tissues of different groups, assessed using RT-qPCR. n = 4–5 per group. k Markers of cardiac hypertrophy (Nppa and Myh7) in diabetic cardiac tissues of different groups, assessed using RT-qPCR. l Cardiac hypertrophy assessed by heart weight/tibia length. n = 4–5 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. DM diabetes mellitus, FTO fat mass and obesity-associated protein, BNP brain natriuretic peptide, MDA malondialdehyde, RT-qPCR quantitative real-time polymerase chain reaction To further validate the role of FTO alleviation of DCM, we treated DCM mice with NMN, which is an important precursor of NAD + that increases FTO expression [26]. NMN treatment had no effect on plasma glucose and body weight (Fig. S3c-d, 3j), upregulated the expression of FTO (Fig. 3a) and significantly improved the heart function of DCM, as evidenced by cardio-ultrasonography and the plasma levels of BNP (Fig. 3b and e). In addition, the results of MDA and Ptgs2 mRNA proved that NMN significantly reduced the FTO-mediated regulation of ferroptosis in DCM (Fig. 3f and g). Correspondingly, indicators of cardiac fibrosis (Fig. 3h and j) and myocardial hypertrophy (Fig. 3k and l), which represent cardiac remodeling, improved after NMN treatment. Collectively, these data furtherly suggested that inhibition of the demethylase activity of FTO aggravate ferroptosis, while enhancing the expression of FTO alleviate ferroptosis in DCM. Enhancing the expression of FTO alleviates ferroptosis in DCM. a FTO expression in cardiac tissues, assessed using western blotting; n = 4–5 per group. b–d Diastolic function in cardiac tissues, assessed using cardio-ultrasonography. n = 4–5 per group. e Heart function assessed based on the plasma levels of BNP. n = 4–5 per group. f Lipid peroxidation in diabetic cardiac tissues, confirmed based on the changes in MDA levels; n = 4–5 per group. g Expression of Ptgs2 in diabetic cardiac tissues, assessed using RT-qPCR. n = 4–5 per group. h Picro-Sirius Red staining results of heart tissue sections. i Quantitative analysis of Picro-Sirius Red staining for collagen accumulation. n = 4–5 per group. j Markers of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf, and Fn1) in diabetic cardiac tissues, assessed using RT-qPCR. n = 4–5 per group. k Markers of cardiac hypertrophy (Nppa and Myh7) in diabetic cardiac tissues, assessed using RT-qPCR. n = 4–5 per group. l Cardiac hypertrophy assessed by heart weight/tibia length. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. DM diabetes mellitus, NMN nicotinamide mononu-cleotide, FTO fat mass and obesity-associated protein, BNP brain natriuretic peptide, MDA malondialdehyde, RT-qPCR quantitative real-time polymerase chain reaction FTO-Mediated Mitigation of Ferroptosis Occurs in an ACSL4-Dependent Manner in DCM To elucidate the regulatory mechanism of FTO in ferroptosis and DCM, we systematically identified its downstream targets through comprehensive bioinformatics analysis, with a specific focus on key regulators of ferroptosis. We retrieved FTO-binding RNA targets in GEO datasets, while simultaneously downloading ferroptosis drivers and suppressors from the FerrDb database. Cross-analysis of ferroptosis-related genes and FTO targets revealed 480 potential regulatory targets (Fig. S1 and Table S1). Subsequent interaction network analysis identified ALKBH5, METTL3, FTH1, ACSL4, and ATF3 as potential downstream targets of FTO. Considering their established roles in m6A modification dynamics, we excluded ALKBH5 (another demethylase) and METTL3 (methyltransferase) from further analysis due to their potential functional redundancy or antagonism with FTO in regulating m6A-dependent processes. Subsequent experimental validation through western blotting demonstrated that FTO overexpression specifically suppressed ACSL4 expression in DCM (Fig. 4a), but not FTH1 or ATF3 (Fig. S2). Conversely, Inhibition of FTO significantly reversed ACSL4 suppression (Fig. 4b), establishing ACSL4 as a bona fide downstream target of FTO-mediated m6A modification in this regulatory network. ACSL4 is a downstream target of FTO in diabetic cardiomyopathy. a ACSL4 expression in cardiac tissues in mice treated with NMN, assessed using western blotting; n = 4–5 per group. b ACSL4 expression in cardiac tissues in mice treated with FB23-2, assessed using western blotting; n = 4–5 per group. c Acls4 expression in AGE-treated ECTs, assessed using RT-qPCR; n = 6 per group. d Acls4 expression in diabetic cardiac tissues, assessed using RT-qPCR; n = 5 per group. e AGE-induced ACSL4 expression in ECTs, assessed using western blotting; n = 6 per group. f ACSL4 expression in diabetic cardiac tissues, assessed using western blotting; n = 5 per group. g ACSL4 expression in control and diabetic cardiac tissues (0, 3, and 6 months after diabetes), assessed using western blotting; n = 4 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. BSA bovine serum albumin, NMN nicotinamide mononucleotide, CKO cardiac conditional knockout, T2DM type 2 diabetes model, DM diabetes mellitus, ACSL4 acyl-CoA synthetase long-chain family 4, AGE advanced glycation end-product, ECT engineered cardiac tissue, RT-qPCR quantitative real-time polymerase chain reaction ACSL4 catalyses the synthesis of long-chain polyunsaturated-CoAs with a preference for arachidonic acid, thus facilitating their esterification into phospholipids, which are eventually the subject of lipid peroxidation [27]. We further investigated the potential involvement of an FTO-mediated ACSL4 transcript demethylation in DCM. We first tested the expression of ACSL4 in both AGE-induced ECT and cardiac tissues of diabetic mice. We found that the mRNA and protein levels of ACSL4 were upregulated in both models (Fig. 4c and f). In addition, ACSL4 levels progressively increased with the extension of diabetes onset (Fig. 4g), which was negatively correlated with FTO expression. Mechanistically, FTO can bind Acsl4 mRNA to decrease its m6A modification, thus reducing the half-life of Acsl4 transcripts [28]. To further investigate the role of ACSL4 and its regulation by FTO in DCM, Acsl4-CKO mice were developed, and Acsl4 knockout efficacy was confirmed (Fig. 5a). Acsl4-CKO had no effect on plasma glucose and body weight (Fig. S3e-f, 3k). The levels of MDA and Ptgs2 mRNA were downregulated in Acsl4-CKO mice (Fig. 5b and c). These results confirm the inhibition of ferroptosis in Acsl4-CKO mice. In addition, Acsl4-CKO mice exhibited suppressed cardiac fibrosis (Fig. 5d and f) and hypertrophy (Fig. 5g and h). Heart function was improved in Acsl4-CKO mice compared with that in control mice with DCM (Fig. 5i and l), indicating a protective effect of Acsl4 knockout on DCM. These observations suggest that ACSL4 was an important molecule responsible for cardiac ferroptosis under the experimental conditions tested, and Acsl4 knockout in cardiac tissue inhibits DCM by targeting ferroptosis. Acsl4 ablation in cardiac tissues alleviates ferroptosis in diabetic cardiomyopathy. a ACSL4 expression in cardiac tissues in control and Acsl4-CKO mice, assessed using western blotting; n = 5 per group. b Lipid peroxidation in diabetic cardiac tissues, confirmed based on changes in MDA levels; n = 5 per group. c Expression of Ptgs2 in diabetic cardiac tissues, assessed using RT-qPCR. n = 5 per group. d Picro-Sirius Red staining results of heart tissue sections. e Quantitative analysis of Picro-Sirius Red staining for collagen accumulation. n = 5 per group. f Markers of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf, and Fn1) in diabetic cardiac tissues, assessed using RT-qPCR. n = 5 per group. g Markers of cardiac hypertrophy (Nppa and Myh7) in diabetic cardiac tissues, assessed using RT-qPCR. n = 5 per group. h Cardiac hypertrophy assessed by heart weight/tibia length. n = 5 per group. i–k Diastolic function, assessed using cardio-ultrasonography. n = 5 per group. l Heart function, assessed based on the plasma levels of BNP. n = 5 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. CKO cardiac conditional knockout, T2DM type 2 diabetes model, ACSL4 acyl-CoA synthetase long-chain family 4, RT-qPCR quantitative real-time polymerase chain reaction, MDA malondialdehyde, BNP brain natriuretic peptide To further investigate the regulation of FTO on ACSL4 in DCM, we treated Acsl4-CKO mice with FTO inhibitor FB23-2 and stimulator NMN. We found Acsl4-CKO abolished the effect of FB23-2 or NMN on ferroptosis and heart function as shown in Fig. 6. Collectively, ACSL4 served as an important player in DCM and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. a Lipid peroxidation in diabetic cardiac tissues of different groups, confirmed by observing the changes in MDA levels; n = 5 per group. b Expression of Ptgs2 in diabetic cardiac tissues of different groups, assessed using RT-qPCR. n = 5 per group. c–e Diastolic function in cardiac tissues of different groups, assessed using cardio-ultrasonography. n = 5 per group. f Heart function in cardiac tissues of different groups, assessed by plasma levels of BNP. n = 5 per group. g Lipid peroxidation in diabetic cardiac tissues of different groups, confirmed by observing the changes in MDA levels; n = 5 per group. h Expression of Ptgs2 in diabetic cardiac tissues of different groups, assessed using RT-qPCR. n = 5 per group. i–k Diastolic function in cardiac tissues of different groups, assessed using cardio-ultrasonography. n = 5 per group. l Heart function in cardiac tissues of different groups, assessed by plasma levels of BNP. n = 5 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. CKO cardiac conditional knockout, T2DM type 2 diabetes model, ACSL4 acyl-CoA synthetase long-chain family 4, MDA malondialdehyde, BNP brain natriuretic peptide SFN Combined with NMN Could Synergistically Inhibit Ferroptosis and Improve Heart Function in DCM Our previous study found SFN could upregulate the expression of SLC7A11 and Ferritin H through activating NRF2, then inhibit ferroptosis and partly rescue heart function in mouse models of DCM [9]. Therefore, we aimed to investigate, whether SFN combined with NMN treatment could synergistically inhibit ferroptosis through different pathways, thereby furtherly improve cardiac function. Mouse models of DCM were treated with NMN, SFN, or NMN + SFN. Through mouse models of DCM, we found SFN combined with NMN treatment had no effect on plasma glucose and body weight (Fig. S3g-h, 3 L), but could significantly and furtherly rescue cardiac function compared to only SFN or NMN treatment (Fig. 7a and d). Finally, we examined the key regulators of ferroptosis-related pathways. NMN + SFN treatment furtherly attenuated the expression of Ptgs2 mRNA in diabetic mice compared to only SFN or NMN treatment (Fig. 7e). The analysis of MDA levels also confirmed that lipid peroxidation was furtherly reduced in NMN + SFN group compared with only SFN or NMN treated mice (Fig. 7f). Furthermore, the markers of cardiac remodeling were furtherly and significantly reduced in cardiac tissue of NMN + SFN treated DCM mice compared to only SFN or NMN treated mice (Fig. 7g and k). Therefore, SFN combined with NMN treatment could synergistically inhibit ferroptosis and improve heart function in DCM. SFN combined with NMN could synergistically inhibit ferroptosis and improve heart function in DCM. a–c Diastolic function, assessed using cardio-ultrasonography. n = 5–6 per group. d Heart function, assessed based on plasma levels of BNP. n = 5–6 per group. e Expression of Ptgs2 in diabetic cardiac tissues, assessed using RT-qPCR. n = 5–6 per group. f Lipid peroxidation in diabetic cardiac tissues of different groups, confirmed based on changes in MDA levels; n = 5–6 per group. g Picro-Sirius Red staining results of heart tissue sections. h Quantitative analysis of Picro-Sirius Red staining for collagen accumulation. n = 5–6 per group. i Markers of cardiac fibrosis (Coll-1α1, Coll-IIIα1, Ctgf, and Fn1) in diabetic cardiac tissues, assessed using RT-qPCR. n = 5–6 per group. j Markers of cardiac hypertrophy (Nppa and Myh7) in diabetic cardiac tissues, assessed using RT-qPCR. n = 5–6 per group. k Cardiac hypertrophy assessed by heart weight/tibia length. n = 5–6 per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. T2D type 2 diabetes model, NMN nicotinamide mononucleotide, SFN sulforaphane, MDA malondialdehyde, RT-qPCR quantitative real-time polymerase chain reaction, BNP brain natriuretic peptide Discussion In this study, we provide evidence that FTO plays a pivotal role in DCM pathogenesis. The downregulation of FTO in DCM, acts as a critical inducer of ferroptosis by increasing the expression of ACSL4 and FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner (Graphic abstract). In addition, enhancing the demethylase activity of FTO with NMN (an antiaging drug) combined with SFN targeting NRF2 could synergistically reduce the level of lipid peroxides to eventually inhibit ferroptosis, providing an effective avenue for alleviating DCM. Although various cell death pathways have been reported to participate in DCM pathogenesis, treatments targeting these processes can only partially rescue heart function [29]. Previous findings including ours suggest that ferroptosis plays an essential role in the pathogenesis of DCM [9, 10]. However, given the complexity of this process, the regulatory mechanisms involved have not yet been fully elucidated. As the most widespread mRNA modification, m6A is globally downregulated and implicated in diabetes and its complications [13, 14]. FTO, which is an m6A demethylase was found to be downregulated in diabetes and its cardiovascular complications [13, 14] and targeting FTO could reduce myocardial fibrosis and myocyte hypertrophy in DCM [13]. However, the underlying mechanism has not been fully defined. In this study, we found that FTO was downregulated in DCM. Further, FTO upregulation effectively inhibited ferroptosis and alleviated DCM. Recent studies have revealed FTO can inhibit ferroptosis in various diseases, including cerebral ischemia/reperfusion injury [30], septic cardiomyopathy [16], doxorubicin-induced cardiotoxicity [15] through the modification of various transcripts. However, the regulatory mechanism of FTO during ferroptosis in DCM remains unclear. Previous studies have demonstrated that FTO overexpression suppressed FYN expression through m6A modification, thereby subduing Drp1 activity and relieving cerebral I/R injury [30]. In addition, downregulated FTO increased the m6A methylation level of GPX4, subsequently recognized by YTHDF2 and degraded, which led to reduced ferroptosis and colorectal cancer growth [31]. In the present study, we found that ACSL4, which is required for polyunsaturated fatty acid-containing phospholipid biosynthesis and ferroptosis [27] is a downstream target of FTO. The decline of FTO in DCM increased the expression of ACSL4, while enhanced FTO reduced the level of it, which was in agreement with a previous finding that FTO overexpression resulted in a shorter half-life of Acsl4 mRNAs [26]. In addition, Acsl4-CKO reduced ferroptosis, inhibited cardiac remodeling and partly rescued heart function in DCM. Furthermore, Acsl4-CKO abolished the effect of FB23-2 and NMN on ferroptosis and heart function, which indicated FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Notably, silencing ACSL4 or stimulating FTO did not completely inhibit cardiac ferroptosis or improve heart function, indicating that combined therapy targeting different regulatory pathways to alleviate ferroptosis and cardiac dysfunction should be pursued further. Currently, treatments for inhibiting ferroptosis are, still in the research stage and are not available for clinical application. In terms of the function of FTO in DCM, drugs that increase FTO demethylase activity may be useful in rescuing heart function in DCM. Recent studies have demonstrated that NAD + enhances the demethylase activity of FTO [32]. As a viable alternative, dietary supplementation with NMN, a critical intermediate in the NAD⁺ biosynthetic pathway—has been shown to efficiently elevate endogenous NAD⁺ levels, thereby circumventing the limitations of direct NAD⁺ delivery [33]. In present study, we also found that NMN could alleviate ferroptosis and improve heart function through enhancing FTO. In addition, based on our previous study that, sulforaphane could prevent ferroptosis and partly rescue heart function via AMPK-mediated NRF2 activation [9], we aimed to define whether combined therapy targeting different regulatory pathways could alleviate ferroptosis and cardiac dysfunction. Here, we demonstrated that SFN combined with NMN treatment could significantly and furtherly inhibit lipid peroxidation and rescue cardiac function in DCM compared to SFN or NMN treatment alone. Notably, although the combined regimen further suppressed ferroptosis and improved cardiac performance, it fell short of complete remission, underscoring that additional, pathways also contribute substantially to the pathogenesis of DCM. This study has some inherent limitations. Firstly, to define the role of FTO in DCM, we initially used the small-molecule inhibitor FB23-2. To strengthen the specificity of our conclusions, we’d better consider more selective inhibitor DAC51 and/or generate a cardiomyocyte-specific FTO knockout (Fto-CKO) model [34]. Secondly, NMN is recognized to engage multiple targets; for instance, NMN supplementation elevates SIRT6 and its downstream effector GPX4 [35]. Consequently, the cardio-protection we document here is unlikely to be mediated exclusively via FTO. Thirdly, the inaccessibility of human DCM myocardial tissue did not allow for direct analysis of patient specimens, which would have offered a more physiologically and clinically meaningful validation of our findings. Additionally, while our therapeutic strategy demonstrated promising results in preclinical models, its clinical translatability and efficacy in human patients require rigorous evaluation through future clinical trials. Conclusion In summary, we provide sufficient data to demonstrate that FTO-mediated mitigation of ferroptosis occurs in an ACSL4-dependent manner in DCM. Synergistic therapy targeting multiple ferroptosis pathways could improve heart function in mice with DCM, providing a basis for further research in this direction. Further clinical trials in humans are needed to evaluate the effects of NMN and SFN on improving heart function in patients with DCM. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author Contributions Xiang W., Conceptualization, Funding acquisition, Methodology, Supervision, Writing, review and editing; XX. C., Conceptualization, Investigation, Methodology, Writing – original draft; Y. G., Formal analysis, Investigation, Methodology; Z. Y., Data curation, Investigation; Methodology; YT. L., Data curation, Investigation; Methodology; ZC. M., performed research; Wei W., Software; YQ. H., Software. Funding This work was supported by the National Natural Science Foundation Youth Program (82200397 to Xiang Wang), the General Project of Natural Science Foundation of Jilin Province (YDZJ202201ZYTS013 to Xiang Wang), Health Talent Project of Jilin Province (JLSWSRCZX2021 to Xiang Wang), and the 2024 Jilin University First Hospital Translational-Clinical Joint Research Fund (to Xiang Wang). Data Availability The data collected for the study can be made available to others upon request and after an evaluation of confidentiality. Declarations Competing Interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The data collected for the study can be made available to others upon request and after an evaluation of confidentiality.